Compare Abbott Laboratories (ABT) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Lufax Holding Ltd — how do they compare? Abbott Laboratories trades at $95.52 (market cap $166.94B), while Lufax Holding Ltd trades at $1.4 (market cap $2.41B). The key difference: Abbott Laboratories is far larger — about 69.3× Lufax Holding Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| ABT | LU | |
|---|---|---|
Market Cap | $166.94B | $2.41B |
Sector | Health | Technology |
52-Week High | $136.62 | $4.40 |
52-Week Low | $82.57 | $1.23 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
LU trades at $1.42, up 1.43% today, with a bullish technical signal but bearish moving averages. The stock shows deep value with a P/S of 0.36 and P/B of 0.1, yet profitability is weak with a -9.08% net margin and negative ROE. Recent news is dominated by a securities class action lawsuit with a May 20, 2026 deadline, creating significant headline risk.
The outlook is mixed; low valuations and a bullish analyst consensus (61.5% buy ratings) suggest potential upside, but negative earnings, cash flow challenges, and legal overhang present substantial risks. Investor sentiment is cautious due to the litigation, making near-term performance highly dependent on case developments and future earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
